Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Apontis Pharma AG's Enterprise Value is €76.18 Mil.
Apontis Pharma AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.98 Mil. Therefore, Apontis Pharma AG's EV-to-OCF for today is -78.05.
The historical rank and industry rank for Apontis Pharma AG's EV-to-OCF or its related term are showing as below:
FRA:APPH'
s EV-to-OCF Range Over the Past 10 Years
Min: -78.05 Med: 0.91 Max: 145
Current: -78.05
During the past 7 years, the highest EV-to-OCF of Apontis Pharma AG was 145.00. The lowest was -78.05. And the median was 0.91.
FRA:APPH's EV-to-OCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 11.045
vs FRA:APPH: -78.05
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apontis Pharma AG (FRA:APPH) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apontis Pharma AG's PE Ratio (TTM) for today is calculated as:
Apontis Pharma AG's share price for today is €11.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €0.078.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apontis Pharma AG EV-to-OCF Related Terms
Apontis Pharma AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's EV-to-OCF falls into.
Apontis Pharma AG's current Enterprise Value is €76.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apontis Pharma AG (FRA:APPH) has a EV-to-OCF of -78.05 as of Aug. 15, 2026.
Is Apontis Pharma AG's EV-to-OCF too high?
Apontis Pharma AG's current EV-to-OCF is -78.05. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's EV-to-OCF compare to ZTS and UTHR?
Apontis Pharma AG's EV-to-OCF of -78.05 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-OCF is 11.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current EV-to-OCF is -78.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current EV-to-OCF of -78.05. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current EV-to-OCF is -78.05. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current EV-to-OCF is -78.05 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
EV-to-OCF: -78.05
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
